Ultragenyx Pharmaceutical (RARE) Capital Expenditures Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 46.88% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.97% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 16.27% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -52.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.17% |
| Dec 31, 2025 | 70.73% |
| Sep 30, 2025 | 35.62% |
| Jun 30, 2025 | 52.97% |
| Mar 31, 2025 | -65.70% |
| Dec 31, 2024 | -78.34% |
| Sep 30, 2024 | -33.90% |
| Jun 30, 2024 | -26.39% |
| Mar 31, 2024 | -57.28% |
| Dec 31, 2023 | -51.66% |
| Sep 30, 2023 | 113.15% |
| Jun 30, 2023 | -40.15% |
| Mar 31, 2023 | -13.46% |
| Dec 31, 2022 | -30.35% |
| Sep 30, 2022 | -35.96% |
| Jun 30, 2022 | -32.69% |
| Mar 31, 2022 | 100.84% |
| Dec 31, 2021 | 137.89% |
| Sep 30, 2021 | 171.09% |
| Jun 30, 2021 | 144.27% |
| Mar 31, 2021 | 225.72% |
| Dec 31, 2020 | 155.55% |
| Sep 30, 2020 | 54.10% |
| Jun 30, 2020 | 121.44% |
| Mar 31, 2020 | 207.46% |
| Dec 31, 2019 | 47.77% |
| Sep 30, 2019 | 18.81% |
| Jun 30, 2019 | 1.28% |
| Mar 31, 2019 | 27.47% |
| Dec 31, 2018 | -14.74% |
| Sep 30, 2018 | -19.50% |
| Jun 30, 2018 | 32.27% |
| Mar 31, 2018 | 1.15% |
| Dec 31, 2017 | -0.93% |
| Sep 30, 2017 | -11.75% |
| Jun 30, 2017 | 44.22% |
| Mar 31, 2017 | -5.19% |
| Dec 31, 2016 | -321.11% |
| Sep 30, 2016 | 145.43% |
| Jun 30, 2016 | 271.93% |
| Mar 31, 2016 | 102.83% |